Bernard V. North
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bernard V. North has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- David Curtis
UCL Genetics Institute, UCL, Darwin Building, Gower Street, London WC1E 6BT
5 shared publications - P. C. Sham
Department of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK
3 shared publications - Amar Ahmad
Public Health Research Center, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates
1 shared publication - Claude Chelala
Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University London, EC1M 6BQ, UK
1 shared publication - Daniel M. Berney
Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK
1 shared publication E. Blaveri
Molecular Psychiatry Laboratory, Windeyer Institute of Medical Sciences, Department of Psychiatry and Behavioural Sciences, Royal Free and University College Medical School, University College London, 46 Cleveland St. London W1T 4JF, UK
1 shared publication
Latest Publications
- Open Access
The Transcriptomic Landscape of Prostate Cancer Development and Progression: An Integrative Analysis
Next-generation sequencing of primary tumors is now standard for transcriptomic studies, but microarray-based data still constitute the majority of available information on other clinically valuable samples, including archive material. Using prostate cancer (PC) as a model, we developed a robust analytical framework to integrate data across different technical platforms and disease subtypes to connect distinct disease stages and reveal potentially relevant genes not identifiable from single studies alone. We reconstructed the molecular profile of PC to yield the first comprehensive insight into its development, by tracking changes in mRNA levels from normal prostate to high-grade prostatic intraepithelial neoplasia, and metastatic disease. A total of nine previously unreported stage-specific candidate genes with prognostic significance were also found. Here, we integrate gene expression data from disparate sample types, disease stages and technical platforms into one coherent whole, to give a global view of the expression changes associated with the development and progression of PC from normal tissue through to metastatic disease. Summary and individual data are available online at the Prostate Integrative Expression Database (PIXdb), a user-friendly interface designed for clinicians and laboratory researchers to facilitate translational research.
Open AccessThe Transcriptomic Landscape of Prostate Cancer Development and Progression: An Integrative Analysis
Next-generation sequencing of primary tumors is now standard for transcriptomic studies, but microarray-based data still constitute the majority of available information on other clinically valuable samples, including archive material. Using prostate cancer (PC) as a model, we developed a robust analytical framework to integrate data across different technical platforms and disease subtypes to connect distinct disease stages and reveal potentially relevant genes not identifiable from single studies alone. We reconstructed the molecular profile of PC to yield the first comprehensive insight into its development, by tracking changes in mRNA levels from normal prostate to high-grade prostatic intraepithelial neoplasia, and metastatic disease. A total of nine previously unreported stage-specific candidate genes with prognostic significance were also found. Here, we integrate gene expression data from disparate sample types, disease stages and technical platforms into one coherent whole, to give a global view of the expression changes associated with the development and progression of PC from normal tissue through to metastatic disease. Summary and individual data are available online at the Prostate Integrative Expression Database (PIXdb), a user-friendly interface designed for clinicians and laboratory researchers to facilitate translational research.
- Open Access
- 31 December 2003
- Published by Springer Nature in BMC Genomic Data
- Vol. 4 (S1) , S74
Mapping loci influencing blood pressure in the Framingham pedigrees using model-free LOD score analysis of a quantitative trait
This paper presents a method of performing model-free LOD-score based linkage analysis on quantitative traits. It is implemented in the QMFLINK program. The method is used to perform a genome screen on the Framingham Heart Study data. A number of markers that show some support for linkage in our study coincide substantially with those implicated in other linkage studies of hypertension.Although the new method needs further testing on additional real and simulated data sets we can already say that it is straightforward to apply and may offer a useful complementary approach to previously available methods for the linkage analysis of quantitative traits.
- 31 December 2003
- Published by Springer Nature in BMC Genomic Data
- Vol. 4 (S1) , S74
Open AccessMapping loci influencing blood pressure in the Framingham pedigrees using model-free LOD score analysis of a quantitative trait
This paper presents a method of performing model-free LOD-score based linkage analysis on quantitative traits. It is implemented in the QMFLINK program. The method is used to perform a genome screen on the Framingham Heart Study data. A number of markers that show some support for linkage in our study coincide substantially with those implicated in other linkage studies of hypertension.Although the new method needs further testing on additional real and simulated data sets we can already say that it is straightforward to apply and may offer a useful complementary approach to previously available methods for the linkage analysis of quantitative traits.
- 15 July 2003
- Published by Wiley in Annals of Human Genetics
- Vol. 67 (4) , 348-356
Assessing Optimal Neural Network Architecture for Identifying Disease‐associated Multi‐marker Genotypes using a Permutation Test, and Application to Calpain 10 Polymorphisms Associated with Diabetes
Biallelic markers, such as single nucleotide polymorphisms (SNPs), provide greater information for localising disease loci when treated as multilocus haplotypes, but often haplotypes are not immediately available from multilocus genotypes in case‐control studies. An artificial neural network allows investigation of association between disease phenotype and tightly linked markers without requiring haplotype phase and without modelling any evolutionary history for the disease‐related haplotypes. The network assesses whether marker haplotypes differ between cases and controls to the extent that classification of disease status based on multi‐marker genotypes is achievable. The network is “trained” to “recognise” affection status based on supplied marker genotypes, and then for each multi‐marker genotype it produces outputs which aim to approximate the associated affection status. Next, the genotypes are permuted relative to affection status to produce many random datasets and the process of training and recording of outputs is repeated. The extent to which the ability to predict affection for the real dataset exceeds that for the random datasets measures the statistical significance of the association between multi‐marker genotype and affection. This permutation test performs well with simulated case‐control datasets, particularly when major gene effects are present. We have explored the effects of systematically varying different network parameters in order to identify their optimal values. We have applied the permutation test to 4 SNPs of the calpain 10 (CAPN10) gene typed in a case‐control sample of subjects with type 2 diabetes, impaired glucose tolerance, and controls. We show that the neural network produces more highly significant evidence for association than do single marker tests corrected for the number of markers genotyped. The use of a permutation test could potentially allow conditional analyses which could incorporate known risk factors alongside marker genotypes. Permuting only the marker genotypes relative to affection status and these risk factors would allow the contribution of the markers to disease risk to be independently assessed.
- 15 July 2003
- Published by Wiley in Annals of Human Genetics
- Vol. 67 (4) , 348-356
Assessing Optimal Neural Network Architecture for Identifying Disease‐associated Multi‐marker Genotypes using a Permutation Test, and Application to Calpain 10 Polymorphisms Associated with Diabetes
Biallelic markers, such as single nucleotide polymorphisms (SNPs), provide greater information for localising disease loci when treated as multilocus haplotypes, but often haplotypes are not immediately available from multilocus genotypes in case‐control studies. An artificial neural network allows investigation of association between disease phenotype and tightly linked markers without requiring haplotype phase and without modelling any evolutionary history for the disease‐related haplotypes. The network assesses whether marker haplotypes differ between cases and controls to the extent that classification of disease status based on multi‐marker genotypes is achievable. The network is “trained” to “recognise” affection status based on supplied marker genotypes, and then for each multi‐marker genotype it produces outputs which aim to approximate the associated affection status. Next, the genotypes are permuted relative to affection status to produce many random datasets and the process of training and recording of outputs is repeated. The extent to which the ability to predict affection for the real dataset exceeds that for the random datasets measures the statistical significance of the association between multi‐marker genotype and affection. This permutation test performs well with simulated case‐control datasets, particularly when major gene effects are present. We have explored the effects of systematically varying different network parameters in order to identify their optimal values. We have applied the permutation test to 4 SNPs of the calpain 10 (CAPN10) gene typed in a case‐control sample of subjects with type 2 diabetes, impaired glucose tolerance, and controls. We show that the neural network produces more highly significant evidence for association than do single marker tests corrected for the number of markers genotyped. The use of a permutation test could potentially allow conditional analyses which could incorporate known risk factors alongside marker genotypes. Permuting only the marker genotypes relative to affection status and these risk factors would allow the contribution of the markers to disease risk to be independently assessed.
- 1 May 2002
- Published by Wiley in Annals of Human Genetics
- Vol. 66 (3) , 235-244
A quick and simple method for detecting subjects with abnormal genetic background in case‐control samples
- 1 May 2002
- Published by Wiley in Annals of Human Genetics
- Vol. 66 (3) , 235-244
A quick and simple method for detecting subjects with abnormal genetic background in case‐control samples
- 1 September 2001
- Published by American Society of Clinical Oncology (ASCO)
- Vol. 65, 473-481
A novel method of two-locus linkage analysis applied to a genome scan for late onset Alzheimer's disease.
A number of methods have previously been described which carry out linkage analysis considering information for two or more loci simultaneously. Apart from some ad hoc methods such as analysing subsamples, these methods use information regarding linkage at all loci under consideration. However, if the actual genotype-specific effects are known for some loci then it would be preferable to consider the genotypes of these loci directly, rather than the amount of allele-sharing they demonstrate. Here we present an extension to our likelihood-based method of model-free linkage analysis as implemented in the MFLINK program. This allows the incorporation of liability classes. The genotypes of a locus known to affect risk can be used to assign subjects to liability classes prior to carrying out linkage tests at other loci. An example application is presented for genome scan data on Alzheimer's disease with analysis conditional on Apoliprotein E (APOE) genotypes. The results provide support for the existence of additional susceptibility loci linked to D10S1211 and to D12S358.
- 1 September 2001
- Published by American Society of Clinical Oncology (ASCO)
- Vol. 65, 473-481
A novel method of two-locus linkage analysis applied to a genome scan for late onset Alzheimer's disease.
A number of methods have previously been described which carry out linkage analysis considering information for two or more loci simultaneously. Apart from some ad hoc methods such as analysing subsamples, these methods use information regarding linkage at all loci under consideration. However, if the actual genotype-specific effects are known for some loci then it would be preferable to consider the genotypes of these loci directly, rather than the amount of allele-sharing they demonstrate. Here we present an extension to our likelihood-based method of model-free linkage analysis as implemented in the MFLINK program. This allows the incorporation of liability classes. The genotypes of a locus known to affect risk can be used to assign subjects to liability classes prior to carrying out linkage tests at other loci. An example application is presented for genome scan data on Alzheimer's disease with analysis conditional on Apoliprotein E (APOE) genotypes. The results provide support for the existence of additional susceptibility loci linked to D10S1211 and to D12S358.
- 1 September 2001
- Published by Wiley in Annals of Human Genetics
- Vol. 65 (5) , 473-482
A novel method of two‐locus linkage analysis applied to a genome scan for late onset Alzheimer's disease
- 1 September 2001
- Published by Wiley in Annals of Human Genetics
- Vol. 65 (5) , 473-482
A novel method of two‐locus linkage analysis applied to a genome scan for late onset Alzheimer's disease